Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG2 | P78540 | 4/20 | 0.50 |
| ▸ | ARG1 | P05089 | 3/20 | 0.50 |
| ▸ | GSR | P00390 | 1/20 | 0.50 |
| ▸ | OTC | P00480 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 6/20 | 0.49 |
| ▸ | NOS1 | P29475 | 5/20 | 0.49 |
| ▸ | NOS3 | P29474 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.44 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.44 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| L-Nil SCHEMBL31540966 | 1.00 | ARG2 (0.50) | ARG2ARG1GSROTCNOS2 | |
| L-Nil SCHEMBL934874 | 1.00 | ARG2 (0.50) | ARG2ARG1GSROTCNOS2 | |
| L-Nil SCHEMBL677147 | 0.98 | ARG2 (0.51) | ARG2ARG1GSROTCNOS2 | |
| L-Nil SCHEMBL1321685 | 0.98 | ARG2 (0.51) | ARG2ARG1GSROTCNOS2 | |
| SCHEMBL8065968 | 0.98 | NOS2 (0.50) | ARG2ARG1GSROTCNOS2 | |
| L-Nil SCHEMBL7977021 | 0.98 | ARG2 (0.51) | ARG2ARG1GSROTCNOS2 | |
| L-Nil SCHEMBL7974005 | 0.98 | ARG2 (0.51) | ARG2ARG1GSROTCNOS2 | |
| Hydrochloric Acid SCHEMBL8470176 | 0.97 | ARG2 (0.50) | ARG2ARG1GSROTCNOS2 | |
| L-Nio SCHEMBL4424485 | 0.95 | OTC (0.54) | ARG2ARG1GSROTCNOS2 | |
| L-Nio SCHEMBL1569333 | 0.95 | OTC (0.54) | ARG2ARG1GSROTCNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 694 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| EP-3338813-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-04-15 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-3558399-B2 | MULTI-LAYER WOUND CARE PRODUCT WITH PERFORATED RELEASE LAYER | BSN MEDICAL GMBH (DE) | 2026-01-14 | — | — | EP | claimed |
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| US-20250276085-A1 | SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-09-04 | — | — | US | claimed |
| US-12251449-B2 | Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase | WILLIAM MARSH RICE UNIVERSITY (US) | 2025-03-18 | — | — | US | claimed |
| US-12163161-B2 | In vitro method for identifying thoracic aortic aneurysms (TAA) in a subject | CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (F.S.P.) (ES) | 2024-12-10 | — | — | US | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| WO-2024224296-A2 | TARGETED PHARMACEUTICAL COMPOSITIONS TO TREAT NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-10-31 | — | — | WO | claimed |
| WO-2004024132-A2 | USE OF NO-SIGNAL CASCADE MODULATORS AND PHARMACEUTICAL COMPOSITION | Eberhard-Karls-Universität Tübingen (DE) | 2004-03-25 | — | — | WO | claimed |
| WO-2004010894-A2 | OPHTHALMOLOGIC IRRIGATION SOLUTIONS AND METHOD | OMEROS CORPORATION (US) | 2004-02-05 | — | — | WO | claimed |
| US-20040023805-A1 | Substituted phenyluracils | ANDREE ROLAND (DE) | 2004-02-05 | — | — | US | claimed |
| US-6649760-B2 | Herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-18 | — | — | US | claimed |
| US-20020173425-A1 | Substituted phenyluracils | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-21 | — | — | US | claimed |
| US-20020156129-A1 | Method of treating pruritus and a pharmaceutical composition for the method | IKEDA MOHANDO CO., LTD. (JP) | 2002-10-24 | — | — | US | claimed |
| WO-2002069910-A2 | USE OF SUBSTANCES THAT PREVENT THAT THE NO SYNTHASE OF WARM-BLOODED ORGANISMS TAKES EFFECT, FOR PRODUCING COSMETIC OR DERMATOLOGICAL PREPARATIONS FOR THE TREATMENT AND/OR THE PROPHYLAXIS OF UNDESIRED SKIN PIGMENTATION | BEIERSDORF AG (DE) | 2002-09-12 | — | — | WO | claimed |
| US-20010031727-A1 | Therapies using hemoproteins | DUKE UNIVERSITY MEDICAL CENTER (US) | 2001-10-18 | — | — | US | claimed |
| EP-1096950-A2 | THERAPIES USING HEMOPROTEINS | DUKE UNIVERSITY MEDICAL CENTER (US) | 2001-05-09 | — | — | EP | claimed |
| WO-2000002580-A2 | THERAPIES USING HEMOPROTEINS | DUKE UNIVERSITY MEDICAL CENTER (US) | 2000-01-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173425-A1 | Substituted phenyluracils | DPYD, POP1, G6PD | ARG2 1111/4885ARG1 1076/4885GSR 267/4885 |
| US-20040023805-A1 | Substituted phenyluracils | DPYD, POP1, G6PD | ARG2 1111/4885ARG1 1076/4885GSR 267/4885 |
| US-12251449-B2 | Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase | STING1, CGAS, GMPS | ARG2 53/4885ARG1 5/4885GSR 1070/4885 |
| US-20250276085-A1 | SYNTHETIC MULTIDOMAIN PEPTIDE BIOMATERIALS THAT INHIBIT INDUCIBLE NITRIC OXIDE SYNTHASE | STING1, CGAS, GMPS | ARG2 53/4885ARG1 5/4885GSR 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.